{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:17:10Z","timestamp":1778919430536,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":11,"publisher":"Springer US","isbn-type":[{"value":"9781071647370","type":"print"},{"value":"9781071647387","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-4738-7_11","type":"book-chapter","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:31:43Z","timestamp":1759271503000},"page":"159-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vivo Evaluation of CTG Repeat-Affected Muscle Pathology in a Myotonic Dystrophy Model Mouse Using Electromyography and Fluorescence In Situ Hybridization"],"prefix":"10.1007","author":[{"given":"Yusuke","family":"Echigoya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsura","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"7","key":"11_CR1","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1212\/wnl.0000000000011425","volume":"96","author":"NE Johnson","year":"2021","unstructured":"Johnson NE, Butterfield RJ, Mayne K, Newcomb T, Imburgia C, Dunn D, Duval B, Feldkamp ML, Weiss RB (2021) Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program. Neurology 96(7):e1045\u2013e1053. https:\/\/doi.org\/10.1212\/wnl.0000000000011425","journal-title":"Neurology"},{"issue":"3","key":"11_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","volume":"32","author":"CA Thornton","year":"2014","unstructured":"Thornton CA (2014) Myotonic dystrophy. Neurol Clin 32(3):705\u2013719, viii. https:\/\/doi.org\/10.1016\/j.ncl.2014.04.011","journal-title":"Neurol Clin"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.drudis.2023.103489","volume":"28","author":"M Pascual-Gilabert","year":"2023","unstructured":"Pascual-Gilabert M, Artero R, L\u00f3pez-Castel A (2023) The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today 28:103489. https:\/\/doi.org\/10.1016\/j.drudis.2023.103489","journal-title":"Drug Discov Today"},{"key":"11_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102390","volume":"67","author":"M Nakamori","year":"2024","unstructured":"Nakamori M, Nakatani D, Sato T, Hasuike Y, Kon S, Saito T, Nakamura H, Takahashi MP, Hida E, Komaki H, Matsumura T, Takada H, Mochizuki H (2024) Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. EClinicalMedicine 67:102390. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102390","journal-title":"EClinicalMedicine"},{"issue":"1","key":"11_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ncn3.12687","volume":"12","author":"M Nakamori","year":"2024","unstructured":"Nakamori M (2024) Expanded-repeat-RNA-mediated disease mechanisms in myotonic dystrophy. Neurol Clin Neurosci 12(1):16\u201323. https:\/\/doi.org\/10.1111\/ncn3.12687","journal-title":"Neurol Clin Neurosci"},{"issue":"9","key":"11_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.molmed.2011.05.004","volume":"17","author":"M Gomes-Pereira","year":"2011","unstructured":"Gomes-Pereira M, Cooper TA, Gourdon G (2011) Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med 17(9):506\u2013517. https:\/\/doi.org\/10.1016\/j.molmed.2011.05.004","journal-title":"Trends Mol Med"},{"issue":"5485","key":"11_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","volume":"289","author":"A Mankodi","year":"2000","unstructured":"Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289(5485):1769\u20131773","journal-title":"Science"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fneur.2018.00519","volume":"9","author":"SO Braz","year":"2018","unstructured":"Braz SO, Acquaire J, Gourdon G, Gomes-Pereira M (2018) Of mice and men: advances in the understanding of neuromuscular aspects of myotonic dystrophy. Front Neurol 9:519. https:\/\/doi.org\/10.3389\/fneur.2018.00519","journal-title":"Front Neurol"},{"issue":"5938","key":"11_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","volume":"325","author":"TM Wheeler","year":"2009","unstructured":"Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325(5938):336\u2013339. https:\/\/doi.org\/10.1126\/science.1173110","journal-title":"Science"},{"issue":"1","key":"11_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/acn3.271","volume":"3","author":"M Nakamori","year":"2016","unstructured":"Nakamori M, Taylor K, Mochizuki H, Sobczak K, Takahashi MP (2016) Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy. Ann Clin Transl Neurol 3(1):42\u201354. https:\/\/doi.org\/10.1002\/acn3.271","journal-title":"Ann Clin Transl Neurol"},{"issue":"7409","key":"11_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111\u2013115. https:\/\/doi.org\/10.1038\/nature11362","journal-title":"Nature"}],"container-title":["Methods in Molecular Biology","Splice Switching"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4738-7_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:58:50Z","timestamp":1778918330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4738-7_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"ISBN":["9781071647370","9781071647387"],"references-count":11,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4738-7_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"1 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}